Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: Involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity

Experimental Neurology

Volumn 228, Issue 1, 2011, Pages 126-137

  Volta, Mattia ^a   Viaro, Riccardo ^a   Trapella, Claudio ^a   Marti, Matteo ^a   Morari, Michele ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

6 OHDA; Basal ganglia; Compound 24; Microdialysis; Nociceptin orphanin FQ; NOP receptor knockouts; Parkinson's disease; Raclopride; Substantia nigra reticulata

Indexed keywords

1 BENZYL N [3 (SPIROISOBENZOFURAN 1 (3H) 4' PIPERIDIN 1 YL)PROPYL]PYRROLIDINE 2 CARBOXAMIDE; 4 AMINOBUTYRIC ACID; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; GLUTAMIC ACID; NOCICEPTIN RECEPTOR; NOCICEPTIN RECEPTOR ANTAGONIST; RACLOPRIDE; UNCLASSIFIED DRUG;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; DRUG SELECTIVITY; LOW DRUG DOSE; MICRODIALYSIS; MOTOR ACTIVITY; MOUSE; NEUROMODULATION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT; SUBSTANTIA NIGRA PARS RETICULATA; THALAMUS;

ANIMALS; DOPAMINE; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; NEURAL PATHWAYS; NEURONS; OPIOID PEPTIDES; PARKINSONIAN DISORDERS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SUBSTANTIA NIGRA; THALAMUS;

EID: 79851508902     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.12.024     Document Type: Article

References (42)

1. Acosta-García J., Hernández-Chan N., Paz-Bermúdez F., Sierra A., Erlij D., Aceves J., Florán B. D4 and D1 dopamine receptors modulate [3H] GABA release in the substantia nigra pars reticulata of the rat. Neuropharmacology 2009, 57:725-730.
2. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989, 12:366-375.
3. Brown J.M., Gouty S., Iyer V., Rosenberger J., Cox B.M. Differential protection against MPTP or metamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression. J. Neurochem. 2006, 98:495-505.
4. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990, 13:281-285.
5. Deniau J.M., Chevalier G. Disinhibition as a basic process in the expression of striatal functions. II. The striato-nigral influence on thalamocortical cells of the ventromedial thalamic nucleus. Brain Res. 1985, 334:227-233.
6. + and 6-OHDA lesioned rats. Neuropharmacology 2009, 56:761-767.
7. Fischetti C., Camarda V., Rizzi A., Pelà M., Trapella C., Guerrini R., McDonald J., Lambert D.G., Salvadori S., Regoli D., Calo' G. Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24. Eur. J. Pharmacol. 2009, 614:50-57.
8. Florin S., Suaudeau C., Meunier J.C., Costentin J. Nociceptin stimulates locomotion and exploratory behaviour in mice. Eur. J. Pharmacol. 1996, 317:9-13.
9. Goto Y., Arai-Otsuki S., Tachibana Y., Ichikawa D., Ozaki S., Takahashi H., Iwasawa Y., Okamoto O., Okuda S., Ohta H., Sagara T. Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity. J. Med. Chem. 2006, 49:847-849.
10. Gouty S., Brown J.M., Rosenberger J., Cox B.M. MPTP treatment increases expression of pre-pro-nociceptin/orphanin FQ mRNA in a subset of substantia nigra reticulata neurons. Neuroscience 2010, 169:269-278.
11. Kuschinsky K., Hornykiewicz O. Morphine catalepsy in the rat: relation to striatal dopamine metabolism. Eur. J. Pharmacol. 1972, 19:119-122.
12. Kuzmin A., Sandin J., Terenius L., Ögren S.O. Evidence in locomotion test for the functional heterogeneity of ORL-1 receptors. Br. J. Pharmacol. 2004, 141:132-140.
13. Lindgren H.S., Andersson D.R., Lagerkvist S., Nissbrandt H., Cenci M.A. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J. Neurochem. 2010, 112:1465-1476.
14. Mabrouk O.S., Marti M., Morari M. Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naive and nociceptin/orphanin FQ receptor knockout mice. Neuroscience 2010, 166:40-48.
15. 2 receptors. J. Neurochem. 2002, 83:635-644.
16. Marti M., Mela F., Veronesi C., Guerrini R., Salvadori S., Federici M., Mercuri N.B., Rizzi A., Franchi G., Beani L., Bianchi C., Morari M. Blockade of nociceptin/orphanin FQ receptor signalling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behaviour. J. Neurosci. 2004, 24:6659-6666.
17. Marti M., Mela F., Guerrini R., Calò G., Bianchi C., Morari M. Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. J. Neurochem. 2004, 91:1501-1504.
18. Marti M., Manzalini M., Bianchi C., Heidbreder C., Morari M., Crespi F. Nociceptin/orphanin FQ modulates neurotransmitter release in the substantia nigra: biochemical and behavioural outcome. The Basal Ganglia VIII 2004, 187-196. Springer, New York. J.C. Bolam, C.A. Ingham, P.J. Magill (Eds.).
19. Marti M., Mela F., Fantin M., Zucchini S., Brown J.M., Witta J., Di Benedetto M., Buzas B., Reinscheid R.K., Salvadori S., Guerrini R., Romualdi P., Candeletti S., Simonato M., Cox B.M., Morari M. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J. Neurosci. 2005, 95:9591-9601.
20. Marti M., Trapella C., Viaro R., Morari M. The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J. Neurosci. 2007, 27:1297-1307.
21. Marti M., Trapella C., Morari M. The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA. J. Neurochem. 2008, 107:1683-1696.
22. Marti M., Viaro R., Guerrini R., Franchi G., Morari M. Nociceptin/Orphanin FQ modulates motor behavior and primary motor cortex output through receptors located in substantia nigra reticulata. Neuropsychopharmacology 2009, 34:341-355.
23. Marti M., Sarubbo S., Latini F., Cavallo M., Eleopra R., Biguzzi S., Lettieri C., Conti C., Simonato M., Zucchini S., Quatrale R., Sensi M., Candeletti S., Romualdi P., Morari M. Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease. Mov. Disord. 2010, 25:1723-1732.
24. Matuszewich L., Yamamoto B.K. Modulation of GABA release by dopamine in the substantia nigra. Synapse 1999, 32:29-36.
25. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., Butour J., Guillemont J.C., Ferrara P., Monsarrat B., Mazaguil H., Vassart G., Parmentier M., Constentin J. Isolation and structure of the endogenus agonist of opioid receptor-like ORL1 receptor. Nature 1995, 377:532-535.
26. Nishi M., Houtani T., Noda Y., Mamiya T., Sato K., Doi T., Kuno J., Takeshima H., Nukada T., Nabeshima T., Yamashita T., Noda T., Sugimoto T. Unrestrained nociceptive response and dysregulation of hearing ability in mice lacking the nociceptin/orphaninFQ receptor. EMBO J. 1997, 16:1858-1864.
27. Norton C.S., Neal C.R., Kumar S., Akil H., Watson S.J. Nociceptin/orphanin FQ and opioid receptor-like receptor mRNA expression in dopamine systems. J. Comp. Neurol. 2002, 444:358-368.
28. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1982, Academic, Sydney.
29. 3 dopamine receptor antagonist activity and limbic selectivity. J. Pharmacol. Exp. Ther. 1997, 280:73-82.
30. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., Grandy D.K., Langen H., Monsma F.J., Civelli O. Orphanin FQ: a neuropeptide that activates an opioid-like G protein-coupled receptor. Science 1995, 270:792-794.
31. Rozas G., Guerra M.J., Labandeira-Garcia J.L. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res. Brain Res. Protoc. 1997, 2:75-84.
32. Sarre S., Yuan H., Jonkers N., Van Hemelrijck A., Ebinger G., Michotte Y. In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6-hydroxydopamine-lesioned rats. J. Neurochem. 2004, 90:29-39.
33. Scatton B., Claustre Y., Cudennec A., Oblin A., Perrault G., Sanger D.J., Schoemaker H. Amisulpride: from animal pharmacology to therapeutic action. Int. Clin. Psychopharmacol. 1997, 12:S29-S36.
34. Schallert T., De Ryck M., Whishaw I.Q., Ramirez V.D., Teitelbaum P. Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of parkinsonism. Exp. Neurol. 1979, 64:33-43.
35. Starr M. Opposing roles of dopamine D1 and D2 receptors in nigral gamma-[3H]aminobutyric acid release?. J. Neurochem. 1987, 49:1042-1049.
36. Viaro R., Sanchez-Pernaute R., Marti M., Trapella C., Isacson O., Morari M. Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. Neurobiol. Dis. 2008, 30:430-438.
37. Viaro R., Marti M., Morari M. Dual motor response to L-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine (MPTP) treated mice: paradoxical inhibition is relieved by D2/D3 receptor blockade. Exp. Neurol. 2010, 223:473-484.
38. Visanji N.P., de Bie R.M., Johnston T.H., McCreary A.C., Brotchie J.M., Fox S.H. The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's Disease. Mov. Disord. 2008, 23:1922-1925.
39. Volta M., Marti M., McDonald J., Molinari S., Camarda V., Pelà M., Trapella C., Morari M. Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1, 2, 3, 6-tetrahydro-pyridin-4-yl]-3-ethyl-1, 3-dihydro-benzoimidazol-2-one (GF-4). Peptides 2010, 31:1194-1204.
40. Volta, M., Mabrouk, O.S., Bido S., Marti, M., Morari, M., 2010b. Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice. J. Neurochem. 115, 1543-1555.
41. Yamamoto B.K., Nash J.F., Gudelsky G.A. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J. Pharmacol. Exp. Ther. 1995, 273:1063-1070.
42. Zheng F., Grandy D.K., Johnson S.W. Actions of orphanin FQ/nociceptin on rat ventral tegmental area neurons in vitro. Br. J. Pharmacol. 2002, 136:1065-1071.